Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DE66 | ISIN: FR0014007ZB4 | Ticker-Symbol: 69O
Frankfurt
06.06.25 | 08:09
1,150 Euro
-0,86 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AELIS FARMA SAS Chart 1 Jahr
5-Tage-Chart
AELIS FARMA SAS 5-Tage-Chart

Aktuelle News zur AELIS FARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Results of Aelis Farma Combined General Meeting of May 27, 2025231Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving...
► Artikel lesen
06.05.Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures246Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving...
► Artikel lesen
29.04.Aelis Farma: Availability of the 2024 Universal Registration Document190Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving...
► Artikel lesen
01.04.Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook3082024 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates: AEF0117: announcement of the results of the Phase 2b clinical...
► Artikel lesen
AELIS FARMA Aktie jetzt für 0€ handeln
26.03.Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117326The purpose of this pioneering Phase 2B trial was to show that AEF0117 reduces cannabis use and to determine the endpoints and optimal dosage to be used in future studies. AEF0117 is the first...
► Artikel lesen
17.02.Aelis Farma Announces Its 2025 Financial Calendar259Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving...
► Artikel lesen
18.11.24Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome339The CB1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and exploratory) objectives of this phase 1/2 performed in young adults with Down...
► Artikel lesen
26.09.24Aelis Farma: Availability of the 2024 Half-year Financial Report282Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year...
► Artikel lesen
25.09.24Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update371A solid cash position of €12.6 million at June 30, 2024, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently...
► Artikel lesen
04.09.24Indivior PLC: Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder451THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN...
► Artikel lesen
04.09.24Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)414The main objective of this phase 2B study was to demonstrate that AEF0117 reduces cannabis use and to determine the endpoints as well as the optimal dosage of AEF0117 for use in future studies....
► Artikel lesen
31.07.24Aelis Farma Announces the Successful Completion of Its Reserved Offering for a Total Gross Amount of €4.5 Million478Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS the "Company"), a...
► Artikel lesen
30.07.24Aelis Farma: Launch of a Reserved Offering of Approximately €5 Million545NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Launch of a Reserved Offering of new shares for c. €5 million aimed at categories...
► Artikel lesen
24.06.24Aelis Farma: Availability of the Description of the Share Buyback Program303Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1